Pre-B lymphoblastic leukemia cells carrying a BCR-ABL1 gene rearrangement exhibit an undifferentiated phenotype. Comparing the genome-wide gene expression profiles of normal B-cell subsets and BCR-ABL1 þ pre-B lymphoblastic leukemia cells by SAGE, the leukemia cells show loss of B lymphoid identity and aberrant expression of myeloid lineage-specific molecules. Consistent with this, BCR-ABL1 þ pre-B lymphoblastic leukemia cells exhibit defective expression of IKAROS, a transcription factor needed for early lymphoid lineage commitment. As shown by inducible expression of BCR-ABL1 in human and murine B-cell precursor cell lines, BCR-ABL1 induces the expression of a dominant-negative IKAROS splice variant, termed IK6. Comparing matched leukemia sample pairs from patients before and during therapy with the BCR-ABL1 kinase inhibitor STI571 (Imatinib), inhibition of BCR-ABL1 partially corrected aberrant expression of IK6 and lineage infidelity of the leukemia cells. To elucidate the contribution of IK6 to lineage infidelity in BCR-ABL1 þ cell lines, IK6 expression was silenced by RNA interference. Upon inhibition of IK6, BCR-ABL1 þ leukemia cells partially restored B lymphoid lineage commitment. Therefore, we propose that BCR-ABL1 induces aberrant splicing of IKAROS, which interferes with lineage identity and differentiation of pre-B lymphoblastic leukemia cells.
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The BCR-ABL1 gene rearrangement resulting from the t(9;22)(q34;q11) translocation represents the most frequent recurrent genetic aberration in B lymphoid leukemia in adults (Look, 1997) . BCR-ABL1 fusion genes encode constitutively active tyrosine kinase molecules mostly of a molecular weight of either 190 or 210 kDa (p190 or p210; Laurent et al., 2001) and BCR-ABL1 kinase activity is required and sufficient to drive malignant transformation of B-cell precursors in mice (Huettner et al., 2000) . Pre-B lymphoblastic leukemia cells carrying a BCR-ABL1 gene rearrangement typically exhibit a differentiation block at the pre-B-cell stage of development (Klein et al., 2004 .
Early B-cell development is guided by a number of transcription factors, including PAX5, E2A, EBF and IKAROS (Busslinger, 2004) . In order to search for downstream targets of BCR-ABL1 that contribute to a differentiation block in BCR-ABL1 þ pre-B lymphoblastic leukemia cells, genome-wide gene expression profiles of this leukemia type were compared with normal hematopoietic progenitor populations by serial analysis of gene expression (SAGE; Velculescu et al., 1995) .
BCR-ABL1 interferes with B lymphoid differentiation in BCR-ABL1
þ pre-B lymphoblastic leukemia cells
Comparing genome-wide gene expression profiles of leukemia cells from two leukemia cases of BCR-ABL1 þ pre-B lymphoblastic leukemia with normal pre-B cells by SAGE, a number of myeloid lineage-specific genes, including transcription factors (MLF2, MZF1, AML1, GATA1), surface receptors (CSF3R, CSF1R, CD14, CD11A) and signaling molecules (IRAK1, MYD88) were upregulated in the pre-B lymphoblastic leukemia cells as in normal myeloid progenitor cells (Figure 1) . Hence, the pattern of gene expression in BCR-ABL1 þ pre-B lymphoblastic leukemia cells as compared to their normal pre-B-cell counterpart is skewed to the myeloid lineage. Consistent with this, transcription factors and signaling molecules involved in early lymphoid differentiation (IKAROS, E2A, IL7Ra, RAG1, RAG2, TdT) and B lymphoid lineage commitment (EBF, PAX5) were silenced in BCR-ABL1 þ pre-B lymphoblastic leukemia cells (Figure 1 ). These findings lead to the hypothesis that lymphoid lineage commitment is impaired in BCR-ABL1 þ pre-B lymphoblastic leukemia cells. We next studied whether derangement of lymphoid lineage commitment and B-cell differentiation in the BCR-ABL1 þ pre-B lymphoblastic leukemia cells are indeed owing to BCR-ABL1 kinase activity. To this end, we induced BCR-ABL1 expression in a murine B lymphoid cell line carrying an inducible BCR-ABL1 transgene (Klucher et al., 1998; Figure 2a and b) . BCR-ABL1 expression was induced by addition of doxycycline as monitored by measurement of BCR-ABL1 mRNA expression and Western blot analysis (Figure 2b ). Induced expression of BCR-ABL1 resulted in upregulation of mRNA levels for the myeloid lineagespecific genes Csfr1 and Gata1 and downregulation of mRNA levels for Il7ra, which is critical for early lymphoid development. Of note, inducible BCR-ABL1 expression also resulted in aberrant splicing of IKAROS, leading to the expression of a dominant-negative form of Ikaros (IK6; Figure 2a ). These findings indicate that BCR-ABL1 can promote lineage infidelity in the murine B-cell precursor line. However, mRNA levels for Oct2, Obf1 and Pax5 remained unchanged.
Attenuation of lymphoid lineage commitment was also linked to BCR-ABL1 kinase activity in BCR-ABL1 þ pre-B lymphoblastic leukemia cells and normal pre-B cells. cDNA synthesis, SAGE analysis, cloning and sequencing of SAGE concatemers was carried out as described previously Mu¨schen et al., 2002; Klein et al., 2003) . A total of 592 000 SAGE tags were collected for 10 SAGE profiles. All SAGE libraries were normalized to 100 000 tags. Leukemia cells from two cases of BCR-ABL1 þ pre-B lymphoblastic leukemia (case II, p190 and case IX, p210; Klein et al., 2004) and normal bone marrow populations and mature B-cell subsets were compared by SAGE. Upregulated genes are depicted in black, downregulated genes in white and intermediate-expressed genes in gray. For each gene, a proposed function with a reference is given. SAGE extracts a 14-bp fragment of any transcript in the analysed cell population as a unique identifier (SAGE tag) of an expressed gene using the reference database UniGene. By counting the number of SAGE tags per 100 000, the representation of a transcript within the transcriptome can be quantified. Normal bone marrow populations analysed
þ memory B cells (MBC) and CD19 þ CD138 þ plasma cells (PC) were analysed. In both leukemia cases (p190 and p210), the cells harbor a V H DJ H gene rearrangement on one allele and a DJ H gene rearrangement on the second allele (Klein et al., 2004) . However, IGK and IGL loci were in germline configuration in both cases (not shown). An IGH VDJ gene rearrangement in the absence of IGK or IGL gene rearrangement defines a pre-B-cell stage of development. We therefore sorted SAGE data based on the ratio of SAGE-tag frequencies in BCR-ABL1 þ pre-B lymphoblastic leukemia cells to normal pre-B cells. SAGE data were sorted according to the ratio between SAGE-tag counts in pre-B cells and in BCR-ABL1 þ ALL cases.
Lineage infidelity in BCR-ABL1 þ pre-B lymphoblastic leukemia cells F Klein et al Figure 2 BCR-ABL1 kinase activity results in lineage infidelity and differentially regulates the expression of lymphoid versus myeloid-specific genes. (a, b) Lymphoid derivative of the murine cell line TONB210 (Klucher et al., 1998) carrying an inducible BCR-ABL1 transgene under the control of a doxycycline-dependent promoter was used for inducible expression of a BCR-ABL1 transgene. The cells were cultured in the presence or absence of 1 mg/ml doxycycline (DOX). In the absence of BCR-ABL1 expression, the cells remain viable in the presence of 2 ng/ml IL-3. BCR-ABL1 expression was induced by addition of 1 mg/ml doxycycline and verified by Western blot analysis (b). EIF4e was used as a loading control. mRNA levels for human BCR-ABL1 and murine Csfr1, Gata1, Pax5, Ikaros splice variants, Il7ra, Oct2, Obf1 and Hprt were monitored (a). From three leukemia patients, matched leukemia sample pairs (patients I-III correspond to cases XIII, XIV and XVIII in Klein et al., 2004) before (white histograms) and during (gray histograms) therapy with the BCR-ABL1 kinase inhibitor STI571 were analysed by flow cytometry for surface expression of GM-CSFRa, IL3Ra, CD13 and IL7Ra (c). One representative case out of three is shown. These patient samples were also subjected to RT-PCR analysis for mRNA expression of IKAROS splice variants, PAX5, IL7Ra and the myeloid transcription factors AML1, GATA1, CEBPa, and normalized for cDNA amounts and leukemia cell content by amplification of BCR-ABL1 and GAPDH cDNA fragments (d). Specificity of the inhibitory effect of STI571 on BCR-ABL1 with respect to B lymphoid versus myeloid lineage markers was tested using three MLL-AF4 þ leukemia cell lines (BEL1, RS4;11 and SEM) that did not carry a BCR-ABL1 gene rearrangement, yet exhibited a mixed lineage (lymphoid/myeloid) phenotype. These three cell lines were cultured in the presence or absence of 10 mmol/l STI571 for 48 h. STI571 had no effect on expression levels (carried out by FACS analysis) of myeloid-lineage related surface molecules GM-CSFRa, IL3Ra and CD13 and the lymphoid lineage marker IL7Ra (not shown). Primers used for semiquantitative RT-PCR analysis are listed in Supplementary Table 1 .
Lineage infidelity in BCR-ABL1 þ pre-B lymphoblastic leukemia cells F Klein et al upregulated IL7Ra surface expression. In agreement with this, we found that inhibition of BCR-ABL1 kinase activity during STI571 therapy results in increased mRNA levels of IL7Ra, while mRNA levels of myeloid transcription factors AML1, GATA1 and CEBPa were downregulated (Figure 2d ).
BCR-ABL1 induces defective expression of IKAROS
Previous studies showed that loss of functional IKAROS prevents normal B-cell development (Georgopoulos et al., 1994; Kirstetter et al., 2002) . Since the expression of a dominant-negative splice variant IK6 can inhibit Bcell differentiation (Tonnelle et al., 2001) , lineage infidelity in human pre-B lymphoblastic leukemia cells may result from BCR-ABL1-induced derangement of IKAROS pre-mRNA splicing, leading to aberrant expression of IK6. Furthermore, the expression of dominant-negative IKAROS splice variants lacking the DNA-binding domain was recently reported in both childhood and adult B-cell lineage acute lymphoblastic leukemia (Sun et al., 1999; Nakase et al., 2000) . Studying IKAROS isoform expression in BCR-ABL1 þ pre-B lymphoblastic leukemia, expression of dominantnegative IK6 was detected in six of seven primary cases (cases XIII-XIX in Klein et al., 2004) and two of three cell lines (in BV173 and SUP-B15, but not in Nalm1 cells). As shown by us and others, BCR-ABL1 can induce aberrant splicing of various genes (Perrotti and Calabretta, 2002) , including SLP65 (Jumaa et al., 2003; Klein et al., 2004) , PYK2 (Salesse et al., 2004) and BTK . Consistent with BCR-ABL1-induced derangement of IKAROS pre-mRNA splicing, patient-derived leukemia cells express dominant-negative IKAROS (IK6) before, but not during extended therapy with the BCR-ABL1 kinase inhibitor STI571 (Figure 2d ).
To directly analyse the effect of BCR-ABL1 expression on IKAROS pre-mRNA splicing in human pre-B lymphoblastic leukemia cells, 697 cells that carry an E2A-PBX1, but not a BCR-ABL1 gene rearrangement, and only exhibit expression of full-length IKAROS were transiently transfected with expression vectors encoding either GFP only or BCR-ABL1 and GFP (Figure 3a) . For both transfections, GFP þ and GFP À cells were sorted and separately analysed for the expression of IKAROS splice variants. Expression of the BCR-ABL1 kinase in transfected cells was verified by Western blot analysis ( Figure 3b ). As shown in Figure 3a , induced expression of BCR-ABL1 results in aberrant splicing of IKAROS, leading to the expression of IK6.
Inhibition of BCR-ABL1 kinase corrects splicing and nuclear localization of IKAROS in pre-B lymphoblastic leukemia cells
Treatment of the leukemia cells with STI571 for 4 days induced selective outgrowth of differentiating subclones that downregulate IL3Ra expression and exhibit surface IgM expression (not shown), which indicates the pre-B to immature B-cell transition . We studied mRNA expression of IKAROS in undifferentiated leukemia cells and in IgM þ MACS-enriched differentiating subclones. Whereas undifferentiated leukemia cells predominantly express dominant-negative IK6, expression of functional IKAROS transcripts was largely restored in IgM þ differentiating subclones (Figure 3c ).
While nuclear localization of IKAROS is critical for its function as a transcription factor, in two untreated leukemia cell lines expressing either p190 or p210 BCR-ABL1 proteins, IKAROS protein is localized in the cytoplasm, which is consistent with the expression of non-DNA-binding IK6 (Figure 3d ). However, differentiating subclones that were MACS-enriched for IgM expression exhibit a nuclear pattern of staining for IKAROS, which is consistent with expression of DNAbinding forms of IKAROS (Figure 3d ).
Silencing of dominant-negative IK6 partially restores B lymphoid lineage commitment
Expression of dominant-negative IK6 can effectively block B-cell differentiation of hematopoietic progenitor cells (HSC) from umbilical cord blood (Tonnelle et al., 2001) . In the absence of functional IKAROS, hematopoietic stem cells cannot give rise to lymphoid cells and are exclusively diverted into the myeloid lineage (Georgopoulos et al., 1994) .
In order to provide evidence for a possible link between the expression of IK6 and lineage infidelity in pre-B lymphoblastic leukemia cells, we silenced IK6 expression in two BCR-ABL1 þ pre-B lymphoblastic leukemia cell lines (SUP-B15 and BV173). Three different siRNA duplices against IK6 and one nontargeting siRNA duplex were used in transfection experiments. All siRNA duplices were labeled with a Cy2 fluorochrome to identify transfected cells. Cy2 þ cells carrying siRNAs were sorted by FACS and subjected to RT-PCR analysis. In both cell lines, IK6 expression was significantly diminished (Figure 4 ). Using cells transfected with a nontargeting siRNA duplex as a reference, mRNA levels for the V(D)J-recombinase molecule RAG1 and the B-cellspecific component of the surrogate light chain l5 were increased, while mRNA levels of the myeloid transcription factor GATA1 were reduced in parallel with IK6. However, no differences were detected for the mRNA expression levels of PAX5 (Figure 4) . Specificity of the IK6-targeting siRNA duplices was controlled by co-amplification of GAPDH mRNA levels, which remained stable (Figure 4) . We conclude that BCR-ABL1-induced expression of IK6 contributes to lineage infidelity observed in BCR-ABL1 þ pre-B lymphoblastic leukemia cells. However, we cannot exclude that molecules other than IK6 also contribute to BCR-ABL1-induced loss of lineage determination. were transfected either with a pool of siRNA duplices targeting IK6 or a nontargeting siRNA duplex serving as a negative control. Three different IK6 siRNAs were designed and synthesized (MWG Biotech, Ebersberg, Germany) to target the junction of exons 2 and 7, which defines the IKAROS splice variant IK6 (sequence data available from EMBL/GenBank under accession number AM085310). The control nontargeting siRNA duplex did not match a known mRNA sequence. The IK6-specific siRNA duplexes were designed according to the guidelines described by Dr Thomas Tuschl at http://www.rockefeller.edu/labheads/tuschl/ sirna.html. All siRNA duplices were labeled with Cy2, using an siRNA labeling kit (Ambion, Austin, TX, USA) according to the manufacturer's protocol. siRNAs were applied to the cells with a final concentration of 100 nmol/l for each siRNA, using Oligofectamine (Invitrogen) in Opti-MEM1 medium (Invitrogen) according to the manufacturer's instructions. After 24 h, leukemia cells were re-transfected with labeled siRNAs and subsequently incubated for further 24 h. The silencing effect of siRNAs for IKAROS isoform IK6 was controlled by RT-PCR analysis of IK6 in Cy2 þ sorted cells. siRNA-transfected cells were subjected to RT-PCR analysis as previously described and investigated for the expression of IKAROS, IK6, PAX5, RAG1, l5, GATA1 and GAPDH. Oligonucleotides used for semiquantitative RT-PCR analysis are listed in Supplementary Table 1.
Figure 3 BCR-ABL1 induces aberrant splicing of IKAROS in human pre-B lymphoblastic leukemia cells. Pre-B lymphoblastic leukemia cells carrying an E2A-PBX1 gene rearrangement were transiently transfected through electroporation with an expression vector encoding only GFP (pMIG_GFP) or BCR-ABL1 and GFP (pMIG_BCR-ABL1/GFP). Expression of the BCR-ABL1 kinase was identified by Western blot analysis (b). EIF4e was used as loading control. At 24 h after electroporation, for each transfection, GFP þ and GFP À cells were sorted, subjected to RNA isolation, cDNA synthesis and analysed for the expression of IKAROS splice variants (a). cDNA amounts were normalized for COX6B mRNA levels. BCR-ABL1 þ pre-B lymphoblastic leukemia cells (BV173) were cultured in the presence or absence of 10 mmol/l STI571 for 4 days. Differentiating IgM þ subclones were enriched by MACS as described previously (Klein et al., 2004) . Undifferentiated BCR-ABL1 þ pre-B lymphoblastic leukemia cells (IgM À ) and differentiating subclones (IgM þ ) were subjected to RT-PCR analysis for IKAROS isoform expression (c). IK6 expression (IKAROS splice variant lacking exons 3-6) was identified by sequence analysis. (Sequence data are available from EMBL/GenBank under accession number AM085310) cDNA amounts were normalized by amplification of BCR-ABL1 fusion transcripts. Localization of IKAROS (d) was studied by confocal laser microscopy in BCR-ABL1 þ pre-B lymphoblastic leukemia cells (BV173 and SUP-B15) expressing either a p210 or a p190 BCR-ABL1 fusion molecule, respectively. For localization of IKAROS, undifferentiated and MACS-enriched IgM þ differentiating subclones were stained with propidium iodide (nucleus) and with anti-IKAROS antibodies (colored image only in HTML version). Nuclear or cytoplasmic localization of IKAROS was analysed using primary antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) together with anti-rabbit IgG-Cy2 (Jackson Immunoresearch). Cells were fixed with 0.4% paraformaldehyde and incubated for 10 min in 90% methanol on ice and subjected to confocal laser-scanning microscopy as described previously (Klein et al., 2003) .
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